The ligand-binding domain of CD22 is needed for inhibition of the B cell receptor signal, as demonstrated by a novel human CD22-specific inhibitor compound

Saved in:
Bibliographic Details
Main Authors: Kelm, Sörge (Author) , Gerlach, Judith (Author) , Brossmer, Reinhard (Author) , Danzer, Claus-Peter (Author) , Nitschke, Lars (Author)
Format: Article (Journal)
Language:English
Published: [May 6, 2002]
In: Journal of experimental medicine
Year: 2002, Volume: 195, Issue: 9, Pages: 1207-1213
ISSN:1540-9538
DOI:10.1084/jem.20011783
Online Access:Aggregator, kostenfrei, Volltext: http://dx.doi.org/10.1084/jem.20011783
Get full text
Author Notes:Soerge Kelm, Judith Gerlach, Reinhard Brossmer, Claus-Peter Danzer, and Lars Nitschke

MARC

LEADER 00000caa a2200000 c 4500
001 1547787953
003 DE-627
005 20230428180841.0
007 cr uuu---uuuuu
008 161007s2002 xx |||||o 00| ||eng c
024 7 |a 10.1084/jem.20011783  |2 doi 
035 |a (DE-627)1547787953 
035 |a (DE-576)477787959 
035 |a (DE-599)BSZ477787959 
035 |a (OCoLC)1340932003 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 32  |2 sdnb 
100 1 |a Kelm, Sörge  |e VerfasserIn  |0 (DE-627)1235032353  |0 (DE-576)165032359  |4 aut 
245 1 4 |a The ligand-binding domain of CD22 is needed for inhibition of the B cell receptor signal, as demonstrated by a novel human CD22-specific inhibitor compound  |c Soerge Kelm, Judith Gerlach, Reinhard Brossmer, Claus-Peter Danzer, and Lars Nitschke 
264 1 |c [May 6, 2002] 
300 |a 7 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 07.10.2016 
700 1 |a Gerlach, Judith  |e VerfasserIn  |4 aut 
700 1 |a Brossmer, Reinhard  |d 1925-2020  |e VerfasserIn  |0 (DE-588)1115343556  |0 (DE-627)869722298  |0 (DE-576)324407076  |4 aut 
700 1 |a Danzer, Claus-Peter  |d 1970-  |e VerfasserIn  |0 (DE-588)124717470  |0 (DE-627)364385588  |0 (DE-576)294464158  |4 aut 
700 1 |a Nitschke, Lars  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t Journal of experimental medicine  |d New York, NY : Rockefeller Univ. Press, 1896  |g 195(2002), 9, Seite 1207-1213  |h Online-Ressource  |w (DE-627)270425594  |w (DE-600)1477240-1  |w (DE-576)078590167  |x 1540-9538  |7 nnas  |a The ligand-binding domain of CD22 is needed for inhibition of the B cell receptor signal, as demonstrated by a novel human CD22-specific inhibitor compound 
773 1 8 |g volume:195  |g year:2002  |g number:9  |g pages:1207-1213  |g extent:7  |a The ligand-binding domain of CD22 is needed for inhibition of the B cell receptor signal, as demonstrated by a novel human CD22-specific inhibitor compound 
856 4 0 |u http://dx.doi.org/10.1084/jem.20011783  |q application/pdf  |x Aggregator  |x Resolving-System  |z kostenfrei  |3 Volltext 
951 |a AR 
992 |a 20161007 
993 |a Article 
994 |a 2002 
998 |g 1115343556  |a Brossmer, Reinhard  |m 1115343556:Brossmer, Reinhard  |d 700000  |d 711000  |e 700000PB1115343556  |e 711000PB1115343556  |k 0/700000/  |k 1/700000/711000/  |p 3 
999 |a KXP-PPN1547787953  |e 2940313814 
BIB |a Y 
SER |a journal 
JSO |a {"physDesc":[{"extent":"7 S."}],"relHost":[{"title":[{"title":"Journal of experimental medicine","subtitle":"JEM","title_sort":"Journal of experimental medicine"}],"pubHistory":["1.1896 -"],"part":{"volume":"195","text":"195(2002), 9, Seite 1207-1213","extent":"7","year":"2002","pages":"1207-1213","issue":"9"},"titleAlt":[{"title":"JEM"}],"disp":"The ligand-binding domain of CD22 is needed for inhibition of the B cell receptor signal, as demonstrated by a novel human CD22-specific inhibitor compoundJournal of experimental medicine","note":["Gesehen am 22.10.08"],"type":{"media":"Online-Ressource","bibl":"periodical"},"recId":"270425594","language":["eng"],"origin":[{"dateIssuedDisp":"1896-","publisher":"Rockefeller Univ. Press","dateIssuedKey":"1896","publisherPlace":"New York, NY"}],"id":{"issn":["1540-9538"],"eki":["270425594"],"zdb":["1477240-1"]},"physDesc":[{"extent":"Online-Ressource"}]}],"name":{"displayForm":["Soerge Kelm, Judith Gerlach, Reinhard Brossmer, Claus-Peter Danzer, and Lars Nitschke"]},"origin":[{"dateIssuedDisp":"[May 6, 2002]","dateIssuedKey":"2002"}],"id":{"eki":["1547787953"],"doi":["10.1084/jem.20011783"]},"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 07.10.2016"],"language":["eng"],"recId":"1547787953","person":[{"family":"Kelm","given":"Sörge","display":"Kelm, Sörge","roleDisplay":"VerfasserIn","role":"aut"},{"family":"Gerlach","given":"Judith","roleDisplay":"VerfasserIn","display":"Gerlach, Judith","role":"aut"},{"family":"Brossmer","given":"Reinhard","display":"Brossmer, Reinhard","roleDisplay":"VerfasserIn","role":"aut"},{"role":"aut","display":"Danzer, Claus-Peter","roleDisplay":"VerfasserIn","given":"Claus-Peter","family":"Danzer"},{"given":"Lars","family":"Nitschke","role":"aut","display":"Nitschke, Lars","roleDisplay":"VerfasserIn"}],"title":[{"title":"The ligand-binding domain of CD22 is needed for inhibition of the B cell receptor signal, as demonstrated by a novel human CD22-specific inhibitor compound","title_sort":"ligand-binding domain of CD22 is needed for inhibition of the B cell receptor signal, as demonstrated by a novel human CD22-specific inhibitor compound"}]} 
SRT |a KELMSOERGELIGANDBIND6200